Ramipril with amlodipine – classic and still effective Review article
Article Sidebar
Published:
Dec 31, 2017
Keywords:
arterial hypertension, amlodipine, ramipril, fixed dose drugs
Main Article Content
Abstract
Arterial hypertension is common condition. Still many patients don’t reach their target blood pressure despite increasing awareness of hypertension. Most of hypertensive patient require 2 or more drugs. Guidelines encourage us to use so called fixed dose drugs. In the meantime we move away from class effect philosophy and pay much more attention to exact drug pharmacological properties and clinical effects. In this article we make a review of date about ramipril and amlodipine. Both are present in cardiology for years. Their connection remains very attractive therapeutic option, still not fully used.
Article Details
How to Cite
Wełnicki , M., Chmielewski , M., Janiszewski , M., & Mamcarz , A. (2017). Ramipril with amlodipine – classic and still effective. Medycyna Faktow (J EBM), 10(4(37), 336-343. https://doi.org/10.24292/01.MF.0417.6
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Tykarski A., Widecka K., Filipiak K.J.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat zmian i ich zasadności. Nadciśn. Tętn. w Prakt. 2015; 2: 71-96.
2. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertension 2006; 10(3): 235-250.
4. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
5. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health-Syst. Pharm. 2000; 57(supl. 1): S3-S7.
6. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
7. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
8. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertension 2017; 21(1): 1-9.
9. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur. Vaiss. 1995; 88(2): 35-42.
10. MacMahon S., Sharpe N., Gamble G. et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
11. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
14. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
15. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging. 2015; 16(8): 834-841.
16. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-828.
19. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93.
20. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 236: 567-573.
21. Mason R.P.: Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action. Am. J. Hypertens. 1998; 11: 245A-249A.
22. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
23. Wydra M., Kuch M.: Amlodypina – state of art. Medycyna Faktów 2013; 2(19): 7-14.
24. Neaton J.D., Grimm R.H., Prineas R.J. et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
25. Pitt B., Byington R.P., Furberg C.D. et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 26: 1503-1510.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.; for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.
27. Jorgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty: results from Coronary AngioPlasty Amlodipine REstenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
29. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
30. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
31. Julius S., Kjeldsen S.E., Brunner H. et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 2003; 16(7): 544-548.
32. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
33. Reichek N., Devereux R.B, Rocha R.A. et al.: Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension. Hypertension 2009; 54: 731-737.
34. Miranda R.D., Mion D. Jr, Rocha J.C. et al.: An 18-Week, Prospective, Randomized, Double-Blind, Multicenter Study of Amlodipine/Ramipril Combination Versus Amlodipine Monotherapy in the Treatment of Hypertension: The Assessment of Combination Therapy of Amlodipine/ Ramipril (ATAR) Study. Clin. Ther. 2008; 30: 1618-1628.
35. Tomcsányi J.: Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fix combination – A non-interventional trial (RAMONA study) (Hungarian). Hypertonia es Nephrologia. 2013; 17: 34-38.
36. Simonyi G.: Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. (Engl). 2016; 129(10): 1224-1228.
37. Simonyi G., Ferenci T.: [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient’s adherence]. Orv. Hetil. 2016; 157(1): 30-34.
2. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertension 2006; 10(3): 235-250.
4. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
5. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health-Syst. Pharm. 2000; 57(supl. 1): S3-S7.
6. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
7. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
8. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertension 2017; 21(1): 1-9.
9. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur. Vaiss. 1995; 88(2): 35-42.
10. MacMahon S., Sharpe N., Gamble G. et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
11. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
14. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
15. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging. 2015; 16(8): 834-841.
16. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-828.
19. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93.
20. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 236: 567-573.
21. Mason R.P.: Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action. Am. J. Hypertens. 1998; 11: 245A-249A.
22. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
23. Wydra M., Kuch M.: Amlodypina – state of art. Medycyna Faktów 2013; 2(19): 7-14.
24. Neaton J.D., Grimm R.H., Prineas R.J. et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
25. Pitt B., Byington R.P., Furberg C.D. et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 26: 1503-1510.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.; for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.
27. Jorgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty: results from Coronary AngioPlasty Amlodipine REstenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
29. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
30. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
31. Julius S., Kjeldsen S.E., Brunner H. et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 2003; 16(7): 544-548.
32. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
33. Reichek N., Devereux R.B, Rocha R.A. et al.: Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension. Hypertension 2009; 54: 731-737.
34. Miranda R.D., Mion D. Jr, Rocha J.C. et al.: An 18-Week, Prospective, Randomized, Double-Blind, Multicenter Study of Amlodipine/Ramipril Combination Versus Amlodipine Monotherapy in the Treatment of Hypertension: The Assessment of Combination Therapy of Amlodipine/ Ramipril (ATAR) Study. Clin. Ther. 2008; 30: 1618-1628.
35. Tomcsányi J.: Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fix combination – A non-interventional trial (RAMONA study) (Hungarian). Hypertonia es Nephrologia. 2013; 17: 34-38.
36. Simonyi G.: Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. (Engl). 2016; 129(10): 1224-1228.
37. Simonyi G., Ferenci T.: [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient’s adherence]. Orv. Hetil. 2016; 157(1): 30-34.